A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects

NCT05846009 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteochondrodysplasia

Interventions

DRUG: SAR442501
DRUG: Placebo

Sponsor

Sanofi